AFLOQUALONE

Possibly Marketed Outside US

Details

Stereochemistry	ACHIRAL
Molecular Formula	C16H14FN3O
Molecular Weight	283.3003
Optical Activity	NONE
Defined Stereocenters	0 / 0
E/Z Centers	0
Charge	0

SHOW SMILES / InChI

Structure Search

SMILES

CC1=CC=CC=C1N2C(=O)C3=C(C=CC(N)=C3)N=C2CF

InChI

InChIKey=VDOSWXIDETXFET-UHFFFAOYSA-N

InChI=1S/C16H14FN3O/c1-10-4-2-3-5-14(10)20-15(9-17)19-13-7-6-11(18)8-12(13)16(20)21/h2-8H,9,18H2,1H3

HIDE SMILES / InChI

Molecular Formula	C16H14FN3O
Molecular Weight	283.3003
Charge	0
Count

Stereochemistry	ACHIRAL
Additional Stereochemistry	No
Defined Stereocenters	0 / 0
E/Z Centers	0
Optical Activity	NONE

Description
Sources: http://www.ncbi.nlm.nih.gov/pubmed/7109348
Curator's Comment: Description was created based on several sources, including https://www.researchgate.net/publication/235333319_Quinazoline_Marketed_drugs_-_A_Review

Afloqualone (AFQ) is one of the centrally acting muscle relaxants. It is a quinazolinone family GABAergic drug and is an analogue of methaqualone developed in the 1970s by a team at Tanabe Seiyaku. It has sedative and muscle-relaxant effects resulting from its agonist activity at the β subtype of the GABAa receptor, and has had some clinical use, although it causes photosensitization as a side-effect that can cause skin problems such as dermatitis.

CNS Activity

Originator

Approval Year

Targets

Primary Target	Pharmacology	Condition	Potency
GABA receptor alpha, Beta subtype, Felis catus 1 Target ID: GABA receptor alpha, Beta subtype, Felis catus Sources: http://www.ncbi.nlm.nih.gov/pubmed/7109348	Agonist 2752

Conditions

Condition	Modality	Targets	Highest Phase	Product
Muscle hypertonia 3 Sources: http://www.ndrugs.com/?s=arofuto	Primary		Approved 8583	Arofuto Approved Use Indications: muscle hypertonia, spastic paralysis
Spastic paralysis 3 Sources: http://www.ndrugs.com/?s=arofuto	Primary		Approved 8583	Arofuto Approved Use Indications: muscle hypertonia, spastic paralysis

C_max

Value	Dose	Co-administered	Analyte	Population
37.9 ng/mL EXPERIMENT https://www.jstage.jst.go.jp/article/jscpt1970/16/4/16_4_649/_article/-char/en	20 mg single, oral dose: 20 mg route of administration: Oral experiment type: SINGLE co-administered:		AFLOQUALONE plasma	Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FED

AUC

Value	Dose	Co-administered	Analyte	Population
245 ng × h/mL EXPERIMENT https://www.jstage.jst.go.jp/article/jscpt1970/16/4/16_4_649/_article/-char/en	20 mg single, oral dose: 20 mg route of administration: Oral experiment type: SINGLE co-administered:		AFLOQUALONE plasma	Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FED

T_1/2

Value	Dose	Co-administered	Analyte	Population
3.34 h EXPERIMENT https://www.jstage.jst.go.jp/article/jscpt1970/16/4/16_4_649/_article/-char/en	20 mg single, oral dose: 20 mg route of administration: Oral experiment type: SINGLE co-administered:		AFLOQUALONE plasma	Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FED

F_unbound

Value	Dose	Co-administered	Analyte	Population
46% OTHER GOV'T https://www.info.pmda.go.jp/go/interview/2/430920_1249008F1215_2_080_1F.pdf#page=17			AFLOQUALONE serum	Homo sapiens

Doses

Dose	Population	Adverse events
40 mg single, oral Studied dose Dose: 40 mg Route: oral Route: single Dose: 40 mg Sources: https://pubmed.ncbi.nlm.nih.gov/1794835/	healthy, ADULT Health Status: healthy Age Group: ADULT Sex: M Food Status: FED Sources: https://pubmed.ncbi.nlm.nih.gov/1794835/	Sources: https://pubmed.ncbi.nlm.nih.gov/1794835/

PubMed

Title	Date	PubMed
Development of a list of potentially inappropriate drugs for the korean elderly using the delphi method.	2010-12	21818443
Exodeviated ophthalmoplegia in a patient with progressive supranuclear palsy.	2009-10	19795006
Comparison between open procedure and tubular retractor assisted procedure for cervical radiculopathy: results of a randomized controlled study.	2009-08	19654947
Induction of eosinophil-infiltrating drug photoallergy in mice.	2009-07	19329284
Evaluation of photoallergic potential of chemicals using THP-1 cells.	2008-11	18693085
Determination of afloqualone in human plasma using liquid chromatography/tandem mass spectrometry: Application to pharmacokinetic studies in humans.	2007-10-15	19073082
Characterization of afloqualone N-glucuronidation: species differences and identification of human UDP-glucuronosyltransferase isoform(s).	2005-01	15475412

Patents

Sample Use Guides

In Vivo Use Guide

Afloqualonen (40 mg) was orally administered

Route of Administration: Oral

In Vitro Use Guide

Afloqualone inhibited spontaneous movements of isolated rabbit atrium and ileum and isolated rat uterus at considerably high concentrations of 10(-6) g/ml or more.

Substance Class	Chemical Created by `admin` on `Wed Apr 02 09:09:24 GMT 2025` Edited by `admin` on `Wed Apr 02 09:09:24 GMT 2025`
Record UNII	CO4U2C8ORZ
Record Status	`Validated (UNII)`
Record Version

Download

Name

Type

Language

AIROMATE

Preferred Name

English

AFLOQUALONE

Official Name

English

Afloqualone [WHO-DD]

Common Name

English

AFLOQUALONE [JAN]

Common Name

English

AFLOQUALONE [MI]

Common Name

English

AFLOQUALONE [MART.]

Common Name

English

afloqualone [INN]

Common Name

English

6-AMINO-2-(FLUOROMETHYL)-3-O-TOLYL-4(3H)-QUINAZOLINONE

Common Name

English

Classification Tree Code System Code

WIKIPEDIA

Designer-drugs-Afloqualone